Cowen & Co. initiated coverage on Nautilus Biotechnology
$NAUT
Biotechnology: Laboratory Analytical Instruments
Industrials
Cowen & Co. initiated coverage of Nautilus Biotechnology with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/27/2024 | $6.00 | Buy | Guggenheim |
| 6/3/2024 | $3.00 | Hold | Jefferies |
| 1/6/2022 | $8.00 | Equal-Weight | Morgan Stanley |
| 11/2/2021 | Outperform | Cowen & Co. | |
| 8/4/2021 | $10.00 | Neutral | Goldman Sachs |
| 7/13/2021 | $13.00 | Buy | Jefferies |
SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke
SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he
SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum
Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.
Jefferies analyst Tycho Peterson assumes Nautilus Biotechnology (NASDAQ:NAUT) with a Hold rating and lowers Price Target of $3.
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and i
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to vie
144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)
144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)
144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)
Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00
Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00
Morgan Stanley initiated coverage of Nautilus Biotechnology with a rating of Equal-Weight and set a new price target of $8.00
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was bestowed the 2024 Distinguished Investigator (DI) Award by the Academy for Radiology and Biomedical Imaging Research (the Academy). The Award recognizes Dr. Mallick's notable achievements in the field of imaging research, including his decades-long leadership, high-impact publications, and ongoing research and development contributions. "Innovation in imaging science is essential for advancing biomedicine
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference. Nautilus' management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Ca
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand